National Cancer Institute   U.S. National Institutes of Health | www.cancer.gov
Application Logo
Model Characteristics - Model: Rat primary brain tumors treated with intralesionally implanted cisplatin 
Model Descriptor Rat primary brain tumors treated with intralesionally implanted cisplatin
Official Nomenclature
Genotype
Species Rat (Rattus norvegicus)
Strain F344 
Is This a Tool Strain? No
Developmental Stage
(applies only to Zebrafish)
 
Experimental Design Chemotherapy has added little to the overall survival of the patients with primary malignant brain tumors, primarily due to its difficulty penetrating the blood-brain barrier. Use of polymers, releasing high doses of chemotherapy locally over time, is a promising new treatment strategy. Three experiments were conducted to test the effect of cisplatin, released from biodegradable polymer, on rats with 1 week established brain tumor.br 9L gliosarcoma cells and drug-free or cisplatin loaded polymer were administered through a right frontal lobe cannula in male Fischer 344 rats. Tumor cells were infused on day 0 and polymer on day 7. Animals were monitored for 60 days. 
Phenotype In experiment one, 0.5 mg/m2 of cisplatin loaded in polymer resulted in a mean survival time (MST) of 51 +/- 14 days with 63% (10/16) rats surviving to day 60. MST for the control group was 24 +/- 4 days (p = 2.5 x 10-9). Evidence of clinical or histologic brain toxicity was minimal. In a second experiment, using drug-free polymer (n=7), MST was 24 +/- 3 days. This was compared against an MST of 24 +/- 4 days in the tumor control group (n=7) and 49 +/- 7 days in a cisplatin-polymer treated group (n=6). In a third experiment, two doses of drug-free polymer and three doses of cisplatin-loaded polymer were tested in normal nontumor-bearing rats and found to be well tolerated.
In conclusion, intralesional sustained release of cisplatin from biodegradable polymer is safe and effective for the treatment of brain 9L gliosarcoma in rats.
Website for add. info  
Breeding Notes

 

Sex Distribution of the Phenotype  
Submitted by caMOD, Curator
Principal Investigator / Lab Lillehei*, Kevin O.
Comment  
 
Model Availability: This model is available from
Strain Distributor Stock number
 
Comments Comments (Please login to submit new comments)
  CONTACT US     DISCLAIMER     ACCESSIBILITY     APPLICATION SUPPORT  
National Cancer Institute Department of Health and Human Services National Institutes of Health FirstGov.gov